Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Insider Transactions

Date Name Title Type Shares Traded Price Range
Jan 15, 2018
Director
Director Grant, award or other acquisition pursuant to Rule 16b-3(d) 200,652 --
Jan 15, 2018
Director
Director Bona fide gift 1,431 --
Jan 15, 2018
Director
Director Other acquisition or disposition -- --
Jan 15, 2018
Director
Director Other acquisition or disposition -- --
Jan 15, 2018
Director
Director Bona fide gift 20,000 --
Jan 15, 2018
Director
Director Other acquisition or disposition -- --
Jan 15, 2018
Director
Director Bona fide gift 774 --
Jan 15, 2018
Director
Director Other acquisition or disposition -- --
Jan 15, 2018
Director, CEO & President
Director, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 175,000 --
Jan 15, 2018
Director, CEO & President
Director, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 38,889 --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 412,500 --
Jan 09, 2018
Director
Director Other acquisition or disposition -- --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 985,444 --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 650,000 $9.18
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 955,847 $11.34
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 500,000 $3.92
Jan 09, 2018
Director
Director Other acquisition or disposition -- --
Jan 09, 2018
Director
Director Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 3,500,294 $18.03
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 500,000 --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 622,376 --
Jan 09, 2018
Director
Director Other acquisition or disposition -- --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 58,480 $6.69
Jan 09, 2018
Director
Director Other acquisition or disposition -- --
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 27,624 $7.24
Jan 09, 2018
Director
Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 985,444 $6.87

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.